```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 09:13:51 ON 21 FEB 2002

=> file caplus uspatful europatful japio medline biosis

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.15       0.15

FILE 'CAPLUS' ENTERED AT 09:14:40 ON 21 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:14:40 ON 21 FEB 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 09:14:40 ON 21 FEB 2002
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 09:14:40 ON 21 FEB 2002
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)

FILE 'MEDLINE' ENTERED AT 09:14:40 ON 21 FEB 2002

FILE 'BIOSIS' ENTERED AT 09:14:40 ON 21 FEB 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s clomipramine or clomipramine(w)salts
<------User Break------>
u
SEARCH ENDED BY USER

=> s clomipramine

L1         6894 CLOMIPRAMINE

=> s l1 and acid(w)addition(w)salt#

L2          131 L1 AND ACID(W) ADDITION(W) SALT#

=> s l2 and premature(w)ejaculation

L3           21 L2 AND PREMATURE(W) EJACULATION

=> s l3 and (buccal? or oral? or transmucosal? or intranasal?)

L4           21 L3 AND (BUCCAL? OR ORAL? OR TRANSMUCOSAL? OR INTRANASAL?)

=> s l4 and (gum or tablet or inhaler or solution)

   3 FILES SEARCHED...
L5           21 L4 AND (GUM OR TABLET OR INHALER OR SOLUTION)

=> s l5 and (fluoxetine or fluvoxamine or paroxetine or sertraline)
```

L6 21 L5 AND (FLUOXETINE OR FLUVOXAMINE OR PAROXETINE OR SERTRALINE)

=> d l6 1-21 ibib abs

L6 ANSWER 1 OF 21 USPATFULL
ACCESSION NUMBER: 2002:4189 USPATFULL
TITLE: Heterocyclic carboxamides
INVENTOR(S): Howard, Harry R., Bristol, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002002168	A1	20020103
APPLICATION INFO.:	US 2001-862691	A1	20010522 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-291352, filed on 14 Apr 1999, GRANTED, Pat. No. US 6277852

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81790	19980415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pfizer Inc., 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 1546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

wherein X, Y, Z, R.sup.2 and R.sup.3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1, agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 21 USPATFULL
ACCESSION NUMBER: 2001:215076 USPATFULL
TITLE: N-acyl and N-aroyl aralkylamides
INVENTOR(S): Howard, Harry R., Bristol, CT, United States
PATENT ASSIGNEE(S): Pfizer INC, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6323229	B1	20011127
APPLICATION INFO.:	US 1999-291454		19990414 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81970	19980416 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bernhardt, Emily
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

wherein m, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are as defined, useful in treating or preventing migraine, depression and other

disorders for which a 5-HT.sub.1 agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 21 USPATFULL
ACCESSION NUMBER: 2001:205912 USPATFULL
TITLE: Heterocyclic carboxamides
INVENTOR(S): Howard, Harry R., Bristol, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041705	A1	20011115
APPLICATION INFO.:	US 2001-862932	A1	20010522 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-291352, filed on 14 Apr 1999, GRANTED, Pat. No. US 6277852

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81790	19980415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pifizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 1548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

wherein X, Y, Z, R.sup.2 and R.sup.3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1, agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 21 USPATFULL
ACCESSION NUMBER: 2001:200173 USPATFULL
TITLE: Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
INVENTOR(S): Howard, Harry Ralph, Bristol, CT, United States
Caron, Stephane, Groton, CT, United States
Adam, Mavis Diane, East Lyme, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001039280	A1	20011108
APPLICATION INFO.:	US 2000-740361	A1	20001219 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-173437	19991229 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pfizer Inc, 235 East 42nd Street, 20th Floor, New York, NY, 10017-5755
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to optically active 3-[(2-

piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical

compositions comprising them and to their medicinal use as selective antagonists of the 5-HT.sub.1D receptor. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT.sub.1D receptor selective antagonist is therapeutically indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 21 USPATFULL

ACCESSION NUMBER:	2001:136655 USPATFULL		
TITLE:	Piperazinyl 5-HT1 agonists and antagonists		
INVENTOR(S):	Howard, Harry R., Bristol, CT, United States		
PATENT ASSIGNEE(S):	Pfizer INC, New York, NY, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277852	B1	20010821
APPLICATION INFO.:	US 1999-291352		19990414 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-81790		19980415 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ford, John M.		
ASSISTANT EXAMINER:	McKenzie, Thomas		
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1385		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1##

or the pharmaceutically acceptable salt thereof, wherein

Z is oxygen, S(O).sub.m wherein m is 0, 1 or 2; or NQ wherein Q is hydrogen, (C.sub.1 -C.sub.6)alkyl or phenyl;

X is hydrogen, chloro, fluoro, bromo, iodo, hydroxy, nitro, cyano, (C.sub.1 -C.sub.6)alkyl, trifluoromethyl, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkyl S(O).sub.a wherein a is 0, 1 or 2; or phenyl wherein the phenyl group is optionally substituted;

Y is ##STR2##

wherein M is oxygen or sulfur;

X.sup.2 is hydrogen, fluoro, chloro, trifluoromethyl, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy or (C.sub.1 -C.sub.6)alkyl S(O).sub.c wherein c is 0, 1 or 2;

R.sup.1 is selected from ##STR3##

wherein R.sup.6 is selected from the group consisting of hydrogen, optionally substituted (C.sub.1 -C.sub.6)alkyl; and wherein R.sup.6 in G.sup.5 together with R.sup.7 form a 2 carbon chain; and R.sup.9 and R.sup.10 are independently hydrogen or (C.sub.1 -C.sub.6)alkyl;

R.sup.2 is hydrogen, (C.sub.1 -C.sub.4)alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally substituted; and

R.sup.3 is --(CH.sub.2).sub.t B, wherein t is 0-3 and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group. These compounds

are useful in treating and preventing a variety of central nervous system diseases, disorders and conditions for which a 5-HT.sub.1, agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 21 USPATFULL
ACCESSION NUMBER: 2001:114631 USPATFULL
TITLE: Administration of active agents, including 5-HT receptor agonists and antagonists, to treat **premature ejaculation**
INVENTOR(S): Smith, William L., Mahwah, NJ, United States
Doherty, Paul C., JR., Cupertino, CA, United States
Place, Virgil A., Kawaihae, HI, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001008896	A1	20010719
APPLICATION INFO.:	US 2001-793839	A1	20010226 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-181071, filed on 27 Oct 1998, GRANTED, Pat. No. US 6228864
Continuation-in-part of Ser. No. US 1997-959061, filed on 28 Oct 1997, GRANTED, Pat. No. US 6037360
Continuation-in-part of Ser. No. US 1997-958571, filed on 28 Oct 1997, GRANTED, Pat. No. US 5922341
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & ASSOCIATES, 3282 ALPINE ROAD, PORTOLA VALLEY, CA, 94028
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, within the context of an effective dosing regimen. The preferred mode of administration is transurethral; however, the selected active agent may also be delivered via intracavernosal injection or using alternative routes. Pharmaceutical formulations and kits are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 21 USPATFULL
ACCESSION NUMBER: 2001:108035 USPATFULL
TITLE: Arylacrylamide derivatives
INVENTOR(S): Howard, Harry Ralph, Bristol, CT, United States
Segelstein, Barbara Eileen, Gales Ferry, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258953	B1	20010710
APPLICATION INFO.:	US 1997-864593		19970528 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Qazi, Sabiha
LEGAL REPRESENTATIVE: Richardson, P. C., Ginsburg, P. H., Joran, A. D.
NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1
LINE COUNT: 1505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are defined as
in the specification. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 21 USPATFULL
ACCESSION NUMBER: 2001:102816 USPATFULL
TITLE: 4-indole derivatives as serotonin agonists and antagonists
INVENTOR(S): Macor, John E., 235 E. 42nd St., Penfield, NY, United States 10017

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255306	B1	20010703
APPLICATION INFO.:	US 1998-132170		19980811 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 776480, now abandoned
Continuation-in-part of Ser. No. US 1994-281192, filed on 26 Jul 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bernhardt, Emily
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth H.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1,2
LINE COUNT: 1939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the formula ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 21 USPATFULL
ACCESSION NUMBER: 2001:67675 USPATFULL
TITLE: Administration of 5-HT receptor agonists and antagonists, to treat **premature ejaculation**
INVENTOR(S): Smith, William L., Mahwah, NJ, United States
Doherty, Jr., Paul C., Cupertino, CA, United States
Place, Virgil A., Kawaihae, HI, United States
PATENT ASSIGNEE(S): Vivus, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228864	B1	20010508
APPLICATION INFO.:	US 1998-181071		19981027 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-959061, filed on 28 Oct 1997, now patented, Pat. No. US 6037360
Continuation-in-part of Ser. No. US 1997-958571, filed on 28 Oct 1997, now patented, Pat. No. US 5922341
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 1238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, within the context of an effective dosing regimen. The preferred mode of administration is transurethral; however, the selected active agent may also be delivered via intracavernosal injection or using alternative routes. Pharmaceutical formulations and kits are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 21 USPATFULL

ACCESSION NUMBER:	2001:33270 USPATFULL
TITLE:	N-acyl and N-aroyl aralkyl amides as serotonergic agents
INVENTOR(S):	Howard, Harry R., Bristol, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197773	B1	20010306
APPLICATION INFO.:	US 2000-584680		20000531 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-291454, filed on 14 Apr 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81970	19980416 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Jarvis, William R. A.
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
LINE COUNT:	1548

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein m, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT.sub.1 agonist or antagonist is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 21 USPATFULL

ACCESSION NUMBER:	2000:174647 USPATFULL
TITLE:	Aryl and heteroaryl alkoxynaphthalene derivatives
INVENTOR(S):	Howard, Jr., Harry R., Bristol, CT, United States Chenard, Bertrand L., Waterford, CT, United States Macor, John E., Penfield, NY, United States Shenk, Kevin D., Groton, CT, United States Desai, Kishor A., Ledyard, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6166020 20001226
APPLICATION INFO.: US 1999-295138 19990420 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 765014
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bernhardt, Emily
LEGAL REPRESENTATIVE: Richardson, Dr. Peter C., Ginsburg, Dr. Paul H., Nissenbaum, Israel
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 2822
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.23, R.sup.24, R.sup.25 and R.sup.26 are defined as in the specification.

These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 21 USPATFULL
ACCESSION NUMBER: 1999:78348 USPATFULL
TITLE: Local administration of pharmacologically active agents
to treat **premature ejaculation**
INVENTOR(S): Smith, William L., Oakland, CA, United States
Place, Virgil A., Kawaihae, HI, United States
PATENT ASSIGNEE(S): VIVUS, Incorporated, Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5922341		19990713	
APPLICATION INFO.:	US 1997-958571		19971028	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos
LEGAL REPRESENTATIVE: Reed, Dianne E.
NUMBER OF CLAIMS: 80
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for delaying the onset of ejaculation in an individual. The method involves administration of a pharmacologically active agent, particularly an antidepressant, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative or analog thereof, within the context of an effective dosing regimen; administration is preferably local, and most preferably is transurethral. Pharmaceutical formulations and kits are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 21 USPATFULL
ACCESSION NUMBER: 1998:134657 USPATFULL
TITLE: Low dose **fluoxetine tablet**
INVENTOR(S): El-Rashidy, Ragab, Deerfield, IL, United States
Ronsen, Bruce, River Forest, IL, United States
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., Wheeling, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5830500 19981103
APPLICATION INFO.: US 1996-681276 19960722 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kulkosky, Peter F.
LEGAL REPRESENTATIVE: Olson & Hierl, Ltd.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A direct compression **tablet** exhibiting relatively low hardness provides a relatively rapid release of **fluoxetine**. The **tablet** has a hardness of no more than about 6 kilopascals and a dicalcium phosphate dihydrate-to-disintegrant weight ratio of about 3 to about 7.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 21 USPATFULL
ACCESSION NUMBER: 97:7930 USPATFULL
TITLE: Compositions containing **sertraline** and a 5-HT.sub.1D receptor agonist or antagonist
INVENTOR(S): Howard, Harry R., New York, NY, United States
Macor, John E., New York, NY, United States
Chenard, Bertrand L., New York, NY, United States
Sprouse, Jeffrey S., New York, NY, United States
Schulz, David W., New York, NY, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5597826		19970128	
APPLICATION INFO.:	US 1994-306230		19940914	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Acquah, Samuel A.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 3659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly

in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including **premature ejaculation**; and chemical dependencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1113015 EUROPATFULL EW 200127 FS OS
TITLE: Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists.
Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selktive 5-HT1D Rezeptor Antagonisten.
Derives de 3-((2-piperazinyl-phenyle)methyle)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone optiquement actifs utilises en tant qu'antagonistes selectifs du recepteurs de 5-HT 1D.
INVENTOR(S): Adam, Mavis Diane, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, US;
Caron, Stephane, Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, US;
Howard, Harry Ralph, Jr., Pfizer Global Res. and Dev., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE(S): Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE NO: 2434221
AGENT: Ruddock, Keith Stephen et al., Pfizer Limited, European Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ, GB
AGENT NUMBER: 75661
OTHER SOURCE: BEPA2001052 EP 1113015 A1 0025
SOURCE: Wila-EPZ-2001-H27-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1113015	A1	20010704
'OFFENLEGUNGS' DATE:		20010704
APPLICATION INFO.: EP 2000-311130		20001213
PRIORITY APPLN. INFO.: US 1999-173437		19991229

L6 ANSWER 16 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1041070 EUROPATFULL EW 200040 FS OS
TITLE: Process for preparing cyclic thioamides.
Verfahren zur Herstellung von cyclischen Thioamiden.
Procede de preparation de thioamides cycliques.
INVENTOR(S): Quallich, George Joseph, Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Raggon, Jeffrey William, Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Hill, Paul David, Pfizer Central Research, Eastern

Point

Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE(S): Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE NO: 2434221
AGENT: Simpson, Alison Elizabeth Fraser et al., Urquhart-Dykes & Lord, 30 Welbeck Street, London W1M 7PG, GB
AGENT NUMBER: 77401
OTHER SOURCE: BEPA2000076 EP 1041070 A1 0024
SOURCE: Wila-EPZ-2000-H40-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1041070	A1	20001004

'OFFENLEGUNGS' DATE: 20001004
APPLICATION INFO.: EP 2000-302110 20000315
PRIORITY APPLN. INFO.: US 1999-126831 19990330

L6 ANSWER 17 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 957099 EUROPATFULL EW 199946 FS OS
TITLE: Heterocyclic carboxamides.
Heterocyclische Carboxamide.
Carboxamides heterocycliques.
INVENTOR(S): Howard, Harry Ralph, 272 Westwoods Terrace, Bristol, Connecticut 06010, US
PATENT ASSIGNEE(S): Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE NO: 2434221
AGENT: Simpson, Alison Elizabeth Fraser et al., Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, GB
AGENT NUMBER: 77401
OTHER SOURCE: ESP1999084 EP 0957099 A2 991117
SOURCE: Wila-EPZ-1999-H46-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 957099	A2	19991117

'OFFENLEGUNGS' DATE: 19991117
APPLICATION INFO.: EP 1999-302288 19990325
PRIORITY APPLN. INFO.: US 1998-81790 19980415

L6 ANSWER 18 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 952154 EUROPATFULL EW 199943 FS OS
TITLE: N-acyl and N-aroyl aralkyl amides.
N-Acyl und N-Aroyl Aralkylamide.
N-acyl et N-aroyl aralkyl amides.
INVENTOR(S): Howard, Harry Ralph, 272 Westwoods Terrace, Bristol, Connecticut 06010, US

PATENT ASSIGNEE(S): Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, US
PATENT ASSIGNEE NO: 2434221
AGENT: Simpson, Alison Elizabeth Fraser et al., Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, GB
AGENT NUMBER: 77401
OTHER SOURCE: ESP1999078 EP 0952154 A2 991027
SOURCE: Wila-EPZ-1999-H43-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 952154	A2	19991027

'OFFENLEGUNGS' DATE: 19991027
APPLICATION INFO.: EP 1999-302284 19990325
PRIORITY APPLN. INFO.: US 1998-81970 19980416

L6 ANSWER 19 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 810220 EUROPATFULL EW 199749 FS OS
TITLE: Arylacrylamide derivatives as 5HT1 agonists or antagonists.
Arylacrylamidderivate als 5HT1 Agonisten oder Antagonisten.
Derives arylacrylamide comme 5HT1 agonistes ou antagonistes.
INVENTOR(S): Howard, Harry Ralph, 272 Westwoods Terrace, Bristol, Connecticut 06010, US;
Segelstein, Barbara Eileen, 16 Woodland Lane, Gales Ferry, Connecticut 06335, US
PATENT ASSIGNEE(S): PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017,
US
PATENT ASSIGNEE NO: 200961
AGENT: Hayles, James Richard et al, Pfizer Limited, Patents Department, Ramsgate Road, Sandwich Kent CT13 9NJ, GB
AGENT NUMBER: 75142
OTHER SOURCE: ESP1997073 EP 0810220 A1 971203
SOURCE: Wila-EPZ-1997-H49-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 810220	A1	19971203

'OFFENLEGUNGS' DATE: 19971203
APPLICATION INFO.: EP 1997-302995 19970501
PRIORITY APPLN. INFO.: US 1996-18580 19960528

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 810220 EUROPATFULL EW 200150 FS PS
TITLE: Arylacrylamide derivatives as 5HT1 agonists or antagonists.
Arylacrylamidderivate als 5HT1 Agoniste oder

Antagoniste.
Derives arylacrylamide comme 5HT1 agonistes ou antagonistes.

INVENTOR(S): Howard, Harry Ralph, 272 Westwoods Terrace, Bristol, Connecticut 06010, US;
Segelstein, Barbara Eileen, 16 Woodland Lane, Gales Ferry, Connecticut 06335, US

PATENT ASSIGNEE(S): PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017,
US

PATENT ASSIGNEE NO: 200961

AGENT: Hayles, James Richard et al., Pfizer Limited, Patents Department, Ramsgate Road, Sandwich Kent CT13 9NJ, GB

AGENT NUMBER: 75142

OTHER SOURCE: BEPB2001068 EP 0810220 B1 0034

SOURCE: Wila-EPS-2001-H50-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 810220	B1	20011212
'OFFENLEGUNGS' DATE:		19971203
APPLICATION INFO.: EP 1997-302995		19970501
PRIORITY APPLN. INFO.: US 1996-18580		19960528
REFERENCE PAT. INFO.: WO 94-21619 A		US 4564685 A

L6 ANSWER 20 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 767782 EUROPATFULL EW 200144 FS PS STA R

TITLE: ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES.
ARYL UND HETEROARYL ALKOXYNAPHTALEN DERIVATE.
DERIVES D'ARYLE ET HETEROARYLE ALKOXYNAPHTALENE.

INVENTOR(S): CHENARD, Bertrand, L., 7 Whaling Drive, Waterford, CT 06385, US;
DESAI, Kishor, A., 31 Seabury Avenue, Ledyard, CT 06339,
US;
HOWARD, Harry, R., Jr., 272 Westwoods Terrace, Bristol, CT 06010, US;
MACOR, John, E., 95 Braeloch Crossing, Penfield, NY 14526, US;
SHENK, Kevin, D., Apartment 201 275 Michelle Lane, Groton, CT 06340, US

PATENT ASSIGNEE(S): PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017,
US

PATENT ASSIGNEE NO: 200961

AGENT: Watkins, David et al., Urquhart-Dykes & Lord, 30 Welbeck
Street, London W1G 8ER, GB

AGENT NUMBER: 77081

OTHER SOURCE: BEPB2001055 EP 0767782 B1 0051

SOURCE: Wila-EPS-2001-H44-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 767782	B1	20011031
'OFFENLEGUNGS' DATE:			19970416
APPLICATION INFO.:	EP 1995-917444		19950518
PRIORITY APPLN. INFO.:	US 1994-268376		19940629
	US 1994-306089		19940914
	US 1994-308320		19940919
RELATED DOC. INFO.:	WO 95-IB381		950518 INTAKZ
	WO 9600720		960111 INTPNR
REFERENCE PAT. INFO.:	EP 434561 A		WO 94-21619 A
REF. NON-PATENT-LIT.:	DRUG DEV. RES. (1991), 22(1), 25-36 CODEN: DDREDK;ISSN: 0272-4391, 19 October 0 GLENNON, RICHARD A. ET AL '5-HT1D serotonin receptors: results of a structure-affinity investigation' cited in the application		

L6 ANSWER 21 OF 21 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 701819 EUROPATFULL EW 199612 FS OS STA R

TITLE: Novel compositions containing **sertraline** and a 5-HT1D receptor agonist or antagonist.
Neue Zusammensetzungen, die Sertralin und einem 5-HT1D-Rezeptoragonisten oder Antagonisten enthalten.
Nouvelles compositions contenant de la **sertraline** et un agoniste ou antagoniste du recepteur 5-HT1D.

INVENTOR(S): Chenard, Bertrand L., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Howard, Harry R., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Macor, John E., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Schulz, David W., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Sprouse, Jeffrey S., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US

PATENT ASSIGNEE(S): PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017,
US

PATENT ASSIGNEE NO: 200961

AGENT: Moore, James William, Dr., Pfizer Limited Ramsgate Road,
Sandwich Kent CT13 9NJ, GB

AGENT NUMBER: 46431

OTHER SOURCE: ESP1996015 EP 0701819 A2 960320

SOURCE: Wila-EPZ-1996-H12-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 701819	A2	19960320
'OFFENLEGUNGS' DATE:			19960320
APPLICATION INFO.:	EP 1995-306249		19950907
PRIORITY APPLN. INFO.:	US 1994-306230		19940914

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 701819 EUROPATFULL EW 200033 FS PS

TITLE: Novel compositions containing **sertraline** and a 5-HT1D receptor agonist or antagonist.
Neue Zusammensetzungen, die Sertralin und einem 5-HT1D-Rezeptoragonisten oder Antagonisten enthalten.
Nouvelles compositions contenant de la **sertraline** et un agoniste ou antagoniste du recepteur 5-HT1D.

INVENTOR(S): Chenard, Bertrand L., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Howard, Harry R., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Macor, John E., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Schulz, David W., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US;
Sprouse, Jeffrey S., c/o Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, US

PATENT ASSIGNEE(S): PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017,
US

PATENT ASSIGNEE NO: 200961

AGENT: Moore, James William, Dr., Pfizer Limited Ramsgate Road,
Sandwich Kent CT13 9NJ, GB

AGENT NUMBER: 46431

OTHER SOURCE: BEPB2000042 EP 0701819 B1 0060

SOURCE: Wila-EPS-2000-H33-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 701819	B1	20000816
'OFFENLEGUNGS' DATE:		19960320
APPLICATION INFO.: EP 1995-306249		19950907
PRIORITY APPLN. INFO.: US 1994-306230		19940914
REFERENCE PAT. INFO.: EP 533268 A		WO 94-21619 A
WO 96-03400 A		